Physician profile
Ewa Czyzewski
NPI 1467473173
$16,168.88
in general payments reported to CMS, 2019-2025
74 companies · $2,459 in 2025
The $2,459 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,651 · 2020: $2,408 · 2021: $2,521 · 2022: $1,559 · 2023: $2,808 · 2024: $2,763 · 2025: $2,459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,030.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,029.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,356.62 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,938.90 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,402.19 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $1,399.99 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Dexcom, INC. | $949.28 | 2021-2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $729.50 | 2019-2025 | Vraylar |
| Pfizer INC. | $669.19 | 2019-2025 | |
| Amgen INC. | $649.77 | 2020-2025 | Repatha, Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $582.73 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $570.78 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $428.95 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Corcept Therapeutics | $273.64 | 2020-2025 | Korlym |
| Allergan, INC. | $273.64 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $259.68 | 2019-2022 | |
| Vifor Pharma, INC. | $242.03 | 2024-2025 | Veltassa |
Show all 74 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ewa Czyzewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.